Regen-D 150 Gel (Recombinant Human Epidermal Growth Factor (150mcg/gm))
|COUNTRY OF ORIGIN||India|
|GENERIC NAME||Recombinant Human Epidermal Growth Factor|
|INDICATION||Diabetic foot ulcers|
|PACKAGING||7.5 gm in 1 tub|
|COMPOSITION||Recombinant Human Epidermal Growth Factor (150mcg/gm)|
Regen-D 150 Gel is used in the treatment of diabetic foot ulcers that occur as a complication of diabetes. It helps in the quick healing of the sores (ulcers) of the leg, ankle, or foot of diabetic patients.
Regen-D 150 Gel accelerates healing and formation of healthy skin, thus providing relief in the skin infection. It is meant for external use only. You should use it in the dose and duration as advised by your doctor. You can help this medication work better by keeping the affected areas clean, making sure they are dry, and washing your hands before and after treating the infection. This medicine should be used regularly to get the most benefit from it. If your condition does not improve or gets worse at any time, let your doctor know. It is advised to use proper footwear to increase the effectiveness of the medicine.
Some common side effects include skin irritation, rash, and pain at the site of application. If the side effects bother you or do not go away, let your doctor know. Some people have a severe allergic reaction that needs urgent medical attention. Signs of this include rash, swelling of the lips, throat, or face, swallowing or breathing problems, dizziness and nausea. Get emergency help if this happens.
It is not likely that other medicines you take by mouth or injection will affect the way it works but talk to your doctor before using it if you have used a similar medicine before and had an allergic reaction. This medicine should only be used if it is clearly needed during pregnancy.
USES OF REGEN-D GEL
- Diabetic foot ulcers
BENEFITS OF REGEN-D GEL
In Diabetic foot ulcers
SIDE EFFECTS OF REGEN-D GEL
Common side effects of Regen-D
- Skin irritation
HOW TO USE REGEN-D GEL
HOW REGEN-D GEL WORKS
There are no reviews yet.